Related Experiment Video
Updated: Jan 23, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
Kai-Li Zhang1,2, Qian-Qian Shen1, Yan-Fen Fang1
1Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Abstract:
Deregulated Polycomb repressive complex 2 (PRC2) is intimately involved in tumorigenesis and progression, making it an invaluable target for epigenetic cancer therapy. Disrupting the EZH2-EED interaction, which is required for PRC2 enzymatic activity, is a promising strategy for cancer treatment. However, this kind of inhibitors are still limited. The in-cell protein-protein interaction screening was conducted for approximately 1300 compounds by NanoBRET technology. Co-immunoprecipitation (Co-IP), protein thermal shift assay (PTSA), and cellular thermal shift assay (CETSA) were performed to investigate the regulation of PRC2 by AZD9291. The anti-tumor effects of AZD9291 on breast cancer (BC) cells and diffuse large B-cell lymphoma (DLBCL) cells were detected. MicroRNA array assay, luciferase reporter assay, and qRT-PCR were conducted to identify the interaction and regulation among AZD9291, EZH2, and miR-34a. We discovered that, AZD9291, a potent and selective EGFR inhibitor, disrupted the interaction of EZH2-EED, leading to impairment of PRC2 activity and downregulation of EZH2 protein. In addition, AZD9291 declined EZH2 mRNA expression via upregulating the expression of a tumor suppressor, miR-34a. Our results suggest that AZD9291 can serve as a lead compound for further development of antagonist of PRC2 protein-protein interactions and EZH2 mRNA may be a direct target of miR-34a through non-canonical base pairing.
Insights
AZD9291, an EGFR inhibitor, disrupts Polycomb repressive complex 2 (PRC2) by inhibiting the EZH2-EED interaction. This epigenetic therapy approach downregulates EZH2 protein and mRNA, showing anti-tumor effects in breast cancer and lymphoma.
Area of Science:
- Epigenetics
- Cancer Biology
- Pharmacology
Background:
- Polycomb repressive complex 2 (PRC2) deregulation drives tumorigenesis.
- Targeting the EZH2-EED interaction is a key epigenetic cancer therapy strategy.
- Existing inhibitors for this interaction are limited.
Purpose of the Study:
- To investigate AZD9291 as a potential disruptor of the EZH2-EED interaction.
- To evaluate the anti-tumor effects of AZD9291 in breast cancer and lymphoma.
- To elucidate the regulatory mechanisms of AZD9291 involving EZH2 and miR-34a.
Main Methods:
- In-cell protein-protein interaction screening using NanoBRET technology.
- Co-immunoprecipitation (Co-IP), PTSA, and CETSA assays to study PRC2 regulation.
- MicroRNA array, luciferase reporter assays, and qRT-PCR to analyze molecular interactions.
Main Results:
- AZD9291, an EGFR inhibitor, disrupts the EZH2-EED interaction, impairing PRC2 activity.
- AZD9291 treatment leads to EZH2 protein downregulation.
- AZD9291 upregulates miR-34a, which in turn downregulates EZH2 mRNA expression.
Conclusions:
- AZD9291 shows potential as a lead compound for developing PRC2 protein-protein interaction antagonists.
- EZH2 mRNA may be a direct target of miR-34a via non-canonical base pairing.
- AZD9291 exhibits anti-tumor effects in breast cancer and diffuse large B-cell lymphoma models.
Related Concept Videos
X-Inactivation
Feedback Inhibition
Activation and Inactivation of G Proteins
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Enzyme Inhibition
Population Growth

